secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2026-06-08T20:04:31+00:00
Accession:  0001339970-26-000039
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma receives Nasdaq extension to Nov 30, 2026 to cure bid price deficiency
--------------------------------------------------------------------------------

- Original bid price deficiency notice received Dec 4, 2025; stock closed below $1.00 for 30 consecutive days.
- On June 3, 2026, Nasdaq granted additional 180-day compliance period until November 30, 2026.
- Company must maintain closing bid price >= $1.00 for 10 consecutive business days to regain compliance.
- aTyr intends to cure deficiency via reverse stock split if necessary during second compliance period.
- Failure to regain compliance by Nov 30, 2026 may result in delisting from Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000039/0001339970-26-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000039/atyr-20260603.htm
  HTML page:      https://secwatch.observer/filing/0001339970-26-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer